'Tocilizumab'
(id=343035570 ; fe=Tocilizumab ; type=1 ; niveau=200 ;
luminosité=25 ;
somme entrante=320 creation date=2024-12-30 touchdate=2025-10-13 07:41:57.000) ≈ 55 relations sortantes
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
angine
n1=Tocilizumab | n2=angine | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
bactériémie
n1=Tocilizumab | n2=bactériémie | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
Bactériémie
n1=Tocilizumab | n2=Bactériémie | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
bactériémie non précisée
n1=Tocilizumab | n2=bactériémie non précisée | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
bactériémies
n1=Tocilizumab | n2=bactériémies | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
chlamydiose
n1=Tocilizumab | n2=chlamydiose | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
douleur de l'estomac
n1=Tocilizumab | n2=douleur de l'estomac | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
écoulement nasal
n1=Tocilizumab | n2=écoulement nasal | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:angina
n1=Tocilizumab | n2=en:angina | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:angina acuta
n1=Tocilizumab | n2=en:angina acuta | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:angina simplex
n1=Tocilizumab | n2=en:angina simplex | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:anginosis
n1=Tocilizumab | n2=en:anginosis | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:bacteraemia
n1=Tocilizumab | n2=en:bacteraemia | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:bacteremia
n1=Tocilizumab | n2=en:bacteremia | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:bacterial infection
n1=Tocilizumab | n2=en:bacterial infection | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:bacterial infections
n1=Tocilizumab | n2=en:bacterial infections | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:bactieremia
n1=Tocilizumab | n2=en:bactieremia | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:chlamydia infection
n1=Tocilizumab | n2=en:chlamydia infection | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:chlamydiosis
n1=Tocilizumab | n2=en:chlamydiosis | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:cough
n1=Tocilizumab | n2=en:cough | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:cynanche
n1=Tocilizumab | n2=en:cynanche | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:nasal discharge
n1=Tocilizumab | n2=en:nasal discharge | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:nasal obstruction
n1=Tocilizumab | n2=en:nasal obstruction | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:pharyngitis
n1=Tocilizumab | n2=en:pharyngitis | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:rhinocleisis
n1=Tocilizumab | n2=en:rhinocleisis | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:sore throat
n1=Tocilizumab | n2=en:sore throat | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:sphagitis
n1=Tocilizumab | n2=en:sphagitis | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:strep
n1=Tocilizumab | n2=en:strep | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:strep throat
n1=Tocilizumab | n2=en:strep throat | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:throat infection
n1=Tocilizumab | n2=en:throat infection | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
en:tonsillitis
n1=Tocilizumab | n2=en:tonsillitis | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
fièvre
n1=Tocilizumab | n2=fièvre | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
frisson
n1=Tocilizumab | n2=frisson | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
infection à Bedsonia
n1=Tocilizumab | n2=infection à Bedsonia | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
infection à Chlamydia
n1=Tocilizumab | n2=infection à Chlamydia | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
infection à chlamydia
n1=Tocilizumab | n2=infection à chlamydia | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
infection à rickettsies
n1=Tocilizumab | n2=infection à rickettsies | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
infection à spirochètes
n1=Tocilizumab | n2=infection à spirochètes | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
Infection bactérienne
n1=Tocilizumab | n2=Infection bactérienne | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
infection bactérienne
n1=Tocilizumab | n2=infection bactérienne | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
infection méningococcique
n1=Tocilizumab | n2=infection méningococcique | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
infections bactériennes
n1=Tocilizumab | n2=infections bactériennes | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
mal de gorge
n1=Tocilizumab | n2=mal de gorge | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
maladie causée par des bactéries
n1=Tocilizumab | n2=maladie causée par des bactéries | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
maladie causée par une bactérie
n1=Tocilizumab | n2=maladie causée par une bactérie | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
maladie infectieuse bactérienne
n1=Tocilizumab | n2=maladie infectieuse bactérienne | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
maladies causées par des bactéries
n1=Tocilizumab | n2=maladies causées par des bactéries | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
maladies causées par une bactérie
n1=Tocilizumab | n2=maladies causées par une bactérie | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
maux de tête
n1=Tocilizumab | n2=maux de tête | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
non précisée, bactériémie
n1=Tocilizumab | n2=non précisée, bactériémie | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
obstruction nasale
n1=Tocilizumab | n2=obstruction nasale | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
toux
n1=Tocilizumab | n2=toux | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
Trachéite
n1=Tocilizumab | n2=Trachéite | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
trouble bactérien infectieux
n1=Tocilizumab | n2=trouble bactérien infectieux | rel=r_has_conseq | relid=41 | w=5
- Tocilizumab --
r_has_conseq #41: 5 / 1 ->
troubles bactériens infectieux
n1=Tocilizumab | n2=troubles bactériens infectieux | rel=r_has_conseq | relid=41 | w=5
| ≈ 0 relations entrantes
|